Atlas Venture, a prominent early-stage venture capital firm focused on transformative biotech innovation, has announced the successful closing of its third Opportunity Fund, which has raised $400 million in an oversubscribed fundraising effort. This new fund will enable Atlas to continue providing essential capital to its portfolio companies as they progress through subsequent financing rounds and advance their therapeutic programs. This announcement follows the closing of Atlas’ $450 million Fund XIV, which took place in December 2024.

"We’ve been encouraged by the incredible progress made across our portfolio, despite the array of challenges faced by biotechs in the current environment. We are thrilled to be in a position to invest Opportunity Fund III into this exceptional cohort of companies," stated the Atlas partnership in a joint statement. They further emphasized that "Opportunity Fund III reinforces our commitment to raising funds tailored in size and strategy to our bespoke investment approach. We are grateful for the support of our longstanding limited partners in our pursuit of building biotechs that can develop transformative therapeutics for patients."

Atlas employs a dual-fund model that features dedicated pools of early-stage and growth capital, allowing for strategic investments in portfolio companies with promising therapeutic programs. Starting with seed and Series A investments from their early-stage funds, the Atlas investment team collaborates with expert entrepreneurs-in-residence to incubate new biotech companies based on promising global scientific discoveries. With the establishment of Opportunity Fund III, Atlas aims to continue meaningful investments in select later-stage private and public financings of existing portfolio companies while maintaining strategic involvement.

With over three decades of experience in building biotechnology companies, Atlas Venture has a proven track record. The firm’s seasoned investment team works seamlessly across both early-stage and opportunity funds to maximize the potential for successful therapeutic development and value recognition. The general partners for Opportunity Fund III include Kevin Bitterman, Bruce Booth, Michael Gladstone, and Jason Rhodes, with Jean-François Formela and David Grayzel continuing to contribute their expertise at Atlas Venture.

About Atlas Venture: Atlas Venture is at the forefront of biotech venture capital, committed to building breakthrough biotech startups for over 30 years. By partnering with exceptional scientists and entrepreneurs, they aim to translate high-impact science into life-saving medicines. Their seed-led venture creation strategy rigorously selects and focuses investments on the most compelling opportunities for building scalable businesses and realizing value. For more information, please visit www.atlasventure.com.